FIGURE 9.
Effect of SKi, S1P, and C2-ceramide on proteasomal activity. Proteasomal luminogenic assays demonstrating the effect of (a) treating MCF-7 Neo cells with C2-ceramide (50 μm, 6 h) or SKi (10 μm, 6 h) or S1P (5 μm, 6 h) on proteasomal activity (100-% of basal luminogenic proteasome activity) against endogenous substrates (n = 3 assays per treatment); (b) treating LNCaP and LNCaP-AI cells with SKi (10 μm, 24 h) on proteasomal activity (100-% of basal luminogenic proteasome activity) in each cell type against endogenous substrates (n = 3 assays per treatment).